Crescent Biopharma, Inc. (CBIO) company profile

The company is a clinical-stage biotechnology company that discovers and develops therapies for the treatment of cancer. Its pipeline includes CR-001, a bispecific antibody designed to bind both PD-1 and VEGF pathways to inhibit immune checkpoints and angiogenesis. It also develops antibody-drug conjugates, such as CR-002, a PD-L1-targeted conjugate delivering a topoisomerase toxin, and CR-003, an integrin beta-6-directed conjugate. The firm focuses on solid tumor oncology indications, including lung, colorectal, and gynecologic malignancies. Its end users are cancer patients with solid tumors requiring monotherapy or combination oncology treatments.

The business conducts clinical development operations across multiple regions, including the United States, Europe, and Asia Pacific, collaborating with Kelun to advance product candidates globally and in Greater China. Although the enterprise converted its legal jurisdiction from Delaware to the Cayman Islands, the provided text does not state its headquarters location or physical facility count.

Summary of the business section of Crescent Biopharma's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“The initial public offering price is $8.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of December 31, 2025, we had 44 full-time employees.”